8 results about "Reduce glutathione" patented technology

The present invention relates to the field of biotechnology, and specifically relates to PxGSTD2 or a mutant thereof, and the use thereof. More specifically, provided is a PxGSTD2 protein mutant comprising a mutation (F205) of a phenylalanine (F) residue at position 205 on the amino acid sequence as shown in SEQ ID NO. 3. Further provided is the use of PxGSTD2 or a mutant thereof in the aspects such as catalyzing the conjugation of a pesticide or Fusarium toxin, such as vomitoxin, with reduced glutathione (GSH), providing a target organism with tolerance to a Fusarium toxin such as vomitoxin, providing a food crop with tolerance or resistance to Fusarium-related diseases or other diseases, improving the yield or quality of a food crop, and improving the tolerance of a non-target organism to pesticides.

The application discloses a kind of attenuated salmonella and amodiaquine combined medicine and application, attenuated salmonella and amodiaquine combined medicine include attenuated salmonella typhimurium VNP20009 and its derivative or genetically modified strain and amodiaquine as active component.Amodiaquine is selectively eliminated neutrophil in tumor microenvironment by targeting binding glutathione reductase in neutrophil and inhibiting its activity.Amodiaquine of the application directly targets glutathione reductase in neutrophil, inhibits its activity, reduces reduced glutathione level, increases active oxygen accumulation, selectively induces neutrophil apoptosis in tumor immune microenvironment, and further enhances the colonization of VNP20009 and its derivative or genetically modified strain in tumor.The combination therapy reduces tumor weight by about 50%, prolongs tumor growth doubling time by 1.5 times, and does not affect the neutrophil level in peripheral blood and important organs, significantly reduces the liver and kidney toxicity of VNP20009 and its derivative or genetically modified strain.

This invention relates to the field of biomedical technology, providing the application of TrxR1 as a target in the prevention and treatment of PLTX toxicity damage. Experimental studies of this invention show that PLTX specifically targets TrxR1, inhibiting or weakening its biological activity. Simultaneously, through the cystine / GSH / GPx4 axis, it leads to a decrease in downstream GSH (reduced glutathione) synthesis, a reduction in glutathione peroxidase 4 (GPX4) activity, and promotes the accumulation of intracellular reactive oxygen species (ROS), Fe... 2+ Elevated levels of PLTX further accelerate lipid peroxidation (LPO), leading to the production of complex compounds such as malondialdehyde (MDA) that mediate ferroptosis. Overexpression of TrxR1, however, can inhibit ferroptosis and reverse PLTX-induced damage. This invention clarifies for the first time the specific molecular damage mechanism of PLTX, contributing to the development of treatment strategies targeting the toxins themselves at both the cellular and molecular levels, and unlocking their potential clinical application value.

The invention discloses a dynamic covalent cross-linked double protein as well as a preparation method and application thereof, and the dynamic covalent cross-linked double protein is constructed by taking lactoferrin and transferrin as raw materials and reduced glutathione as a tool to enable the lactoferrin and the transferrin to be subjected to disulfide bond exchange reaction. The method comprises the following steps: (1) respectively dissolving lactoferrin and transferrin in a phosphate buffer solution to obtain a lactoferrin solution and a transferrin solution; (2) mixing the solutions, adding reduced glutathione, and oscillating and incubating in a water bath; (3) adding EDTA to terminate the reaction; and (4) dialyzing to remove the free reduced glutathione, thereby obtaining the product. According to the lactoferrin-transferrin compound disclosed by the invention, the bacteriostatic and antioxidant functions of the two proteins are synergistically enhanced, the stability of the lactoferrin-transferrin compound in a weakly acidic environment to a weakly alkaline environment is remarkably improved, and the encapsulation efficiency of the monascus yellow liposome is improved from 55.25% to 76.25%.

The application provides an AKG-containing anti-aging functional food raw material with improved metabolic absorption rate, which is composed of the following components in parts by weight: diketopiperazine (AKG) 10-30 parts, black pepper extract 1-5 parts, turmeric 5-15 parts, and glutathione 8-20 parts; wherein the content of piperine in the black pepper extract is not less than 95%; and the glutathione is reduced glutathione with a purity of not less than 98.0%. The application takes AKG as a core synergistic absorption carrier, fully utilizes its inherent properties of regulating intestinal microenvironment, promoting intestinal mucosal repair, and activating absorption-related signal pathways, and forms a closed-loop synergy with the metabolic enzyme inhibition of black pepper extract, the intestinal anti-inflammatory effect of turmeric extract, and the antioxidant protection effect of glutathione, so as to crack the oral absorption barrier of the three core functional components from multiple dimensions and improve the metabolic absorption rate.

The invention provides application of Qixuekang in preparation of a medicine for treating renal fibrosis. Experimental research proves that the Qixuekang administration can remarkably recover the renal function of a mouse with renal fibrosis in senescence-accompanied chronic kidney diseases, reduce the mouse kidney mesenchymal fibrosis level and the levels of fibrosis markers alpha-SMA and Col1, recover the content of reductive glutathione in the mouse, improve the activity of superoxide dismutase and improve the curative effect of the kidney fibrosis in the senescence-accompanied chronic kidney diseases. Therefore, kidney fibrosis phenotypes and fibrosis-related biochemical indexes of mice are improved. Qi-blood Kang can remarkably restore kidney mesenchymal transformation related gene and protein expression, and kidney fibrosis phenotypes in chronic kidney diseases are improved by reducing related inflammatory media; qiwankang can significantly improve mitochondrial membrane potential, increase mitochondrial neogenesis related gene expression and reduce generation of active oxygen.

This invention provides a ligase buffer and its product, and its application in mRNA tailing, relating to the field of nucleic acid synthesis technology. The invention provides a T4 DNA ligase buffer comprising Tris-HCl, ATP, MgCl2, reduced glutathione (GSH), polyvinylpyrrolidone K30 (PVP K30), and Triton X-100; this buffer significantly improves the ligation efficiency of T4 DNA ligase and can be applied to mRNA tailing based on enzyme digestion and ligation.